{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:13:06Z","timestamp":1790082786400,"version":"4.0.1"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000145"],"award-info":[{"award-number":["82000145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003875"],"award-info":[{"award-number":["82003875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170143"],"award-info":[{"award-number":["82170143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M702875"],"award-info":[{"award-number":["2021M702875"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LD22H310005"],"award-info":[{"award-number":["LD22H310005"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.taap.2023.116585","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T02:09:37Z","timestamp":1686276577000},"page":"116585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions"],"prefix":"10.1016","volume":"473","author":[{"given":"Ri Han","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Han","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liaqat","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Naranmandura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2023.116585_bb0005","article-title":"Management of acute myeloid leukemia (AML) in older patients","volume":"103","author":"Abdallah","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.taap.2023.116585_bb0010","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-el-Enein","year":"2021","journal-title":"Blood. Cancer. Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus Type II FLT3 inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0025","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.taap.2023.116585_bb0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0035","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2023.116585_bb0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/asheducation.V2012.1.143.3798224","article-title":"Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen","volume":"2012","author":"Brentjens","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.taap.2023.116585_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.639387","article-title":"IDH1\/IDH2 inhibition in acute myeloid leukemia","volume":"11","author":"Cerchione","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0050","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.taap.2023.116585_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720930614","article-title":"Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation","volume":"11","author":"Chew","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.taap.2023.116585_bb0060","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.taap.2023.116585_bb0065","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0070","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1200\/JCO.2016.34.15_suppl.7008","article-title":"Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML","volume":"34","author":"Cortes","year":"2016","journal-title":"JCO"},{"key":"10.1016\/j.taap.2023.116585_bb0075","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","article-title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD\u2013mutated, relapsed or refractory AML","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0080","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0085","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2019-128648","article-title":"Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0090","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0095","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2023.116585_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26136","article-title":"A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia","volume":"96","author":"Daver","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.taap.2023.116585_bb0105","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ccell.2017.10.002","article-title":"Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure","volume":"32","author":"de Th\u00e9","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.taap.2023.116585_bb0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-022-00687-5","article-title":"Resistance to targeted therapies: delving into FLT3 and IDH","volume":"12","author":"Desikan","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.taap.2023.116585_bb0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13148-016-0237-y","article-title":"A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers","volume":"8","author":"Diesch","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.taap.2023.116585_bb0120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.taap.2023.116585_bb0125","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0135","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2023.116585_bb0140","series-title":"Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML)","author":"Dinardo","year":"2020"},{"key":"10.1016\/j.taap.2023.116585_bb0145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0155","article-title":"Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML","volume":"100971","author":"Drula","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.taap.2023.116585_bb0160","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.3390\/cancers12113087","article-title":"CD123 as a biomarker in hematolymphoid malignancies: principles of detection and targeted therapies","volume":"12","author":"El Achi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.taap.2023.116585_bb0165","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-07-866095","article-title":"FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias","volume":"133","author":"Esnault","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101244","article-title":"FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia","volume":"15","author":"Fang","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0175","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/sj.leu.2404720","article-title":"CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease","volume":"21","author":"Fevery","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2023.116585_bb0180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40259-021-00477-8","article-title":"CAR-T cell therapy for acute myeloid leukemia: Preclinical rationale, current clinical progress, and barriers to success","volume":"35","author":"Fiorenza","year":"2021","journal-title":"BioDrugs."},{"key":"10.1016\/j.taap.2023.116585_bb0185","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"JCO"},{"key":"10.1016\/j.taap.2023.116585_bb0190","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Galanis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0195","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.3390\/cancers13225608","article-title":"Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance","volume":"13","author":"Garciaz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.taap.2023.116585_bb0200","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1470-2045(22)00410-7","article-title":"Epidemiology and outcomes of acute promyelocytic leukaemia in the era of all-trans retinoic acid (ATRA) chemotherapy and arsenic trioxide plus ATRA: a retrospective analysis","volume":"23","author":"Gill","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0205","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.tips.2022.04.006","article-title":"Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules","volume":"43","author":"Goebel","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2023.116585_bb0210","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1021\/acs.jmedchem.2c00397","article-title":"Selectivity through targeted protein degradation (TPD)","volume":"65","author":"Gopalsamy","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.taap.2023.116585_bb0215","doi-asserted-by":"crossref","DOI":"10.1158\/2643-3230.BCD-22-0126","article-title":"CAR T cells contend with myeloma in the bone marrow microenvironment","author":"Graham","year":"2022","journal-title":"Blood. Cancer. Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0220","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1158\/1078-0432.CCR-20-2149","article-title":"Development of highly optimized antibody\u2013drug conjugates against CD33 and CD123 for acute myeloid leukemia","volume":"27","author":"Han","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2023.116585_bb0225","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0230","doi-asserted-by":"crossref","DOI":"10.1200\/CCI.22.00030","article-title":"Machine learning\u2013based exploratory clinical decision support for newly diagnosed patients with acute myeloid leukemia treated with 7 + 3 type chemotherapy or venetoclax\/azacitidine","author":"Islam","year":"2022","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.taap.2023.116585_bb0235","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.taap.2023.116585_bb0240","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: update 2017","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.taap.2023.116585_bb0245","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1182\/bloodadvances.2021004424","article-title":"Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia","volume":"5","author":"Kaeding","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.taap.2023.116585_bb0250","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.taap.2023.116585_bb0255","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.taap.2023.116585_bb0260","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOH.0000000000000567","article-title":"Driver mutations in acute myeloid leukemia","volume":"27","author":"Kishtagari","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.taap.2023.116585_bb0265","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.taap.2023.116585_bb0270","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: an unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0275","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.taap.2023.116585_bb0280","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a Phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0285","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.taap.2023.116585_bb0290","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exphem.2022.04.001","article-title":"Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia","volume":"111","author":"Kropp","year":"2022","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.taap.2023.116585_bb0295","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood-2013-06-505115","article-title":"Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?","volume":"122","author":"Lallemand-Breitenbach","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0300","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0305","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/JBM.S100283","article-title":"Midostaurin: an emerging treatment for acute myeloid leukemia patients","volume":"7","author":"Lazarus","year":"2016","journal-title":"JBM"},{"key":"10.1016\/j.taap.2023.116585_bb0310","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1080\/10428194.2017.1403600","article-title":"Targeting oncoproteins for degradation by small molecules in myeloid leukemia","volume":"59","author":"Lei","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.taap.2023.116585_bb0315","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0320","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1200\/JCO.2009.21.8487","article-title":"Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers","volume":"27","author":"Lewis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0325","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-021-01146-7","article-title":"Protein degradation technology: a strategic paradigm shift in drug discovery","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0330","article-title":"FLT3-TKD in the prognosis of patients with acute myeloid leukemia: a meta-analysis","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0335","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1080\/10428194.2020.1775212","article-title":"Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD","volume":"61","author":"Liang","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.taap.2023.116585_bb0340","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.7150\/jca.29751","article-title":"Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells","volume":"11","author":"Liu","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.taap.2023.116585_bb0345","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/jcb.21770","article-title":"Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy","volume":"104","author":"L\u00fcbbert","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.taap.2023.116585_bb0350","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2643-3230.BCD-20-0188","article-title":"Hyperthermia selectively destabilizes oncogenic fusion proteins","volume":"2","author":"Maimaitiyiming","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.34133\/2022\/9802969","article-title":"Heat treatment promotes ubiquitin-mediated proteolysis of SARS-CoV-2 rna polymerase and decreases viral load","volume":"2022","author":"Maimaitiyiming","year":"2022","journal-title":"Research"},{"key":"10.1016\/j.taap.2023.116585_bb0360","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T cells for acute myeloid leukemia: state of the art and future directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0365","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0370","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","article-title":"FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia","volume":"110","author":"Mead","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0375","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/leu.2015.91","article-title":"Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms","volume":"29","author":"Molenaar","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2023.116585_bb0380","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41388-017-0077-z","article-title":"Wild-type and mutated IDH1\/2 enzymes and therapy responses","volume":"37","author":"Molenaar","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.taap.2023.116585_bb0385","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147805","article-title":"AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation","author":"Montesinos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0390","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.taap.2023.116585_bb0395","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bbrc.2019.11.007","article-title":"Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells","volume":"521","author":"Mu","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2023.116585_bb0400","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"The Oncologist"},{"key":"10.1016\/j.taap.2023.116585_bb0405","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2012-07-444018","article-title":"Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target","volume":"121","author":"Park","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0410","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/leu.2015.147","article-title":"Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia","volume":"29","author":"Park","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2023.116585_bb0415","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3390\/ijms24032718","article-title":"CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm","volume":"24","author":"Pelosi","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.taap.2023.116585_bb0420","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2023.116585_bb0425","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2643-3230.BCD-21-0050","article-title":"Genetic and transcriptional contributions to relapse in normal karyotype acute myeloid leukemia","volume":"3","author":"Petti","year":"2021","journal-title":"Blood. Cancer. Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0430","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2023.116585_bb0435","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.taap.2023.116585_bb0440","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.389.389","article-title":"Results of a phase II study of crenolanib in relapsed\/refractory acute myeloid leukemia patients (Pts) with activating FLT3 mutations","author":"Randhawa","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0445","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.taap.2023.116585_bb0450","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-Gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.taap.2023.116585_bb0460","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg1655","article-title":"DNA methylation and human disease","volume":"6","author":"Robertson","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.taap.2023.116585_bb0465","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.taap.2023.116585_bb0475","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/cells9112493","article-title":"Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing challenges and future treatments","volume":"9","author":"Scholl","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.taap.2023.116585_bb0480","doi-asserted-by":"crossref","DOI":"10.2174\/2210315511666210512025010","article-title":"Development of metal-based drugs and application in clinical treatment","volume":"12","author":"Shao","year":"2022","journal-title":"NPJ"},{"key":"10.1016\/j.taap.2023.116585_bb0485","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/2643-3230.BCD-20-0210","article-title":"Understanding FLT3 inhibitor resistance to rationalize combinatorial AML therapies","volume":"2","author":"Shastri","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0490","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0495","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0500","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2023.116585_bb0505","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.taap.2023.116585_bb0510","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.3390\/cancers12113225","article-title":"Advances in acute myeloid leukemia: recently approved therapies and drugs in development","volume":"12","author":"Stanchina","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.taap.2023.116585_bb0515","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0520","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0525","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0530","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.3390\/jcm10163556","article-title":"Antibody-drug conjugates for the treatment of acute pediatric leukemia","volume":"10","author":"Stokke","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.taap.2023.116585_bb0535","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2023.116585_bb0540","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0545","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with aFLT3Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2023.116585_bb0550","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.taap.2023.116585_bb0555","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000496870","article-title":"Chimeric antigen receptor T cells: a race to revolutionize cancer therapy","volume":"46","author":"Subklewe","year":"2019","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.taap.2023.116585_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2020.11.005","article-title":"The RUNX1\/RUNX1T1 network: translating insights into therapeutic options","volume":"94","author":"Swart","year":"2021","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.taap.2023.116585_bb0565","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3390\/ijms22041944","article-title":"Emerging immunotherapy for acute myeloid leukemia","volume":"22","author":"Tabata","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.taap.2023.116585_bb0570","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group","volume":"21","author":"Taksin","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2023.116585_bb0575","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s12264-022-00866-1","article-title":"Advances in the immunotherapeutic potential of isocitrate dehydrogenase mutations in glioma","volume":"38","author":"Tang","year":"2022","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.taap.2023.116585_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101522","article-title":"Evolving of treatment paradigms and challenges in acute promyelocytic leukaemia: a real-world analysis of 1105 patients over the last three decades","volume":"25","author":"Teng-Fei","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.taap.2023.116585_bb0585","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.3390\/cancers13164113","article-title":"A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.taap.2023.116585_bb0590","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2643-3230.BCD-21-0160","article-title":"Integrated genomic analysis identifies UBTF tandem duplications as a recurrent lesion in pediatric acute myeloid leukemia","volume":"3","author":"Umeda","year":"2022","journal-title":"Blood. Cancer. Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0595","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1158\/2643-3230.BCD-22-0067","article-title":"CAR T-cell therapy meets clonal hematopoiesis","volume":"3","author":"Uslu","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0600","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","author":"Uy","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.taap.2023.116585_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101103","article-title":"Beyond midostaurin: which are the most promising FLT3 inhibitors in AML?","volume":"32","author":"Wang","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.taap.2023.116585_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115299","article-title":"Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia","volume":"409","author":"Wang","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116585_bb0615","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1039\/c9mt00308h","article-title":"Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases","volume":"12","author":"Wang","year":"2020","journal-title":"Metallomics."},{"key":"10.1016\/j.taap.2023.116585_bb0620","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/2643-3230.BCD-22-0011","article-title":"Pharmacogenomic profiling of pediatric acute myeloid leukemia to identify therapeutic vulnerabilities and inform functional precision medicine","volume":"3","author":"Wang","year":"2022","journal-title":"Blood. Cancer. Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0625","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1111\/bjh.18061","article-title":"Venetoclax for arsenic-resistant acute promyelocytic leukaemia","volume":"197","author":"Wang","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.taap.2023.116585_bb0630","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0635","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.taap.2023.116585_bb0640","article-title":"PML\/RAR\u03b1 destabilization by hyperthermia: a new model for oncogenic fusion protein degradation?","author":"Wu","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0645","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/2643-3230.BCD-20-0230","article-title":"MYC and TFEB control dna methylation and differentiation in AML","volume":"2","author":"Wu","year":"2021","journal-title":"Blood. Cancer. Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0650","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2217\/imt-2020-0277","article-title":"Therapeutic cancer vaccine therapy for acute myeloid leukemia","volume":"13","author":"Wu","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.taap.2023.116585_bb0655","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2023.116585_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215603","article-title":"Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies","volume":"533","author":"Yao","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.taap.2023.116585_bb0665","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ccr.2013.03.005","article-title":"R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis","volume":"23","author":"Ye","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.taap.2023.116585_bb0670","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40364-020-00196-2","article-title":"Advances in targeted therapy for acute myeloid leukemia","volume":"8","author":"Yu","year":"2020","journal-title":"Biomark Res."},{"key":"10.1016\/j.taap.2023.116585_bb0675","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0680","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood-2019-126065","article-title":"Final clinical results of a phase II study of high dose cytarabine followed by pembrolizumab in relapsed\/refractory AML","volume":"134","author":"Zeidner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0685","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood. Cancer. Discov."},{"key":"10.1016\/j.taap.2023.116585_bb0690","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40364-019-0170-2","article-title":"Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia","volume":"7","author":"Zhao","year":"2019","journal-title":"Biomark Res."},{"key":"10.1016\/j.taap.2023.116585_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.taap.2023.116585_bb0700","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116585_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112539","article-title":"PROTAC: a promising technology for cancer treatment","volume":"203","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.taap.2023.116585_bb0710","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1056\/NEJMc1316382","article-title":"Resistance to arsenic therapy in acute promyelocytic leukemia","volume":"370","author":"Zhu","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2023.116585_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.931462","article-title":"The molecular mechanisms of resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Zhuang","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23002247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23002247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:01:56Z","timestamp":1758574916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23002247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":142,"alternative-id":["S0041008X23002247"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116585","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116585"}}